Bamlanivimab + etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with B-cell malignancies
Ce dossier présente un ensemble d'articles concernant la prise en charge des cancers durant la crise sanitaire liée au COVID-19
Bamlanivimab and etesevimab are IgG1 monoclonal antibodies (mAbs) that bind to SARS-CoV-2 spike receptor-binding domain. Treatment with bamlanivimab 2800 mg and etesevimab 2800 mg has been shown to significantly reduce SARS-CoV-2 viral load at day 11 in mild to moderate COVID-19 patients.1 In the phase III part of the BLAZE-1 trial, the risk of COVID-related hospitalization or death was reduced by 70% in patients treated with this combination versus placebo.
Annals of Oncology , éditorial en libre accès, 2021